Xcout Intel
Cumulus Oncology
Cumulus Oncology operates Europe's first oncology biotech creation engine, identifying promising therapeutic assets and spinning out specialized companies. Headquartered in Edinburgh, Scotland, the company secured £9m in seed financing to accelerate its oncology drug development model. It employs a lean team dedicated to oncology asset creation.
Subscribe to see Cumulus Oncology’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Cumulus Oncology at a glance
Cumulus Oncology is a biotechnology company headquartered in United Kingdom. Its most recent funding round, Seed, raised $11.4M in January 2024.
Cumulus Oncology funding rounds
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Seed | $11.4M | 3 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Investors
Cumulus Oncology competitors
A few of Cumulus Oncology's closest competitors — see the full list of competitors and alternatives →
PhoreMost Ltd is a Cambridge, United Kingdom-based biotechnology and drug discovery company dedicated to turning scientific breakthroughs into life-changing cancer therapies.
Crescendo Biologics Ltd., associated with originator organization Crescendo Bioscience LLC, is a biotechnology company headquartered in Cambridge, UK. The firm develops targeted drug pipelines, particularly focusing on oncology and PSMA-positive castration-resistant prostatic cancer treatments.
Cleara Biotech is a preclinical-stage biotechnology company headquartered in Utrecht, the Netherlands. The company develops targeted therapeutics aimed at clearing impaired-p53 cells to treat cancer and chronic diseases. It secured seed funding to advance its innovative pipeline of anti-aging and oncology treatments.
Nimbus Therapeutics is a biotechnology company that uses structure-based drug discovery and computational chemistry to develop small-molecule medicines. It focuses on therapeutic areas including oncology, autoimmune disease, and metabolic disorders, serving patients through internally developed programs and pharmaceutical partnerships.
Get Cumulus Oncology's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Cumulus Oncology in Xcout Intel
- 1 funding round with the investors in each, and who they co-invest with
- The full competitor set, tracking, exports and API access